The Copernicus Group IRB

The Copernicus Group IRB

The Copernicus Group IRB was founded in Durham, North Carolina, and serves as an independent institutional review board for clinical trials. Its core function is ethical oversight: reviewing study protocols, informed consent documents, and safety data to protect human subjects in biomedical research, a role mandated by the U.S. Department of Health and Human Services under 45 CFR 46. The firm focuses on the healthcare services sector, serving pharmaceutical, biotech, and medical device companies that outsource IRB review for operational efficiency and regulatory compliance. As an IRB organization, the Copernicus Group does not deploy capital or pursue investment returns. Its revenue derives from review fees charged to sponsors, and its operational footprint is concentrated in the United States, with Durham as the primary base. The firm handles a range of trial types, including multi-site studies and emergency-use protocols, but public information on the number of staff or active reviews is limited. The business model aligns with the broader trend of for-profit, centralized IRBs competing with academic and non-profit boards. The Copernicus Group lacks a disclosed founder, team size, or parent entity in public records as of mid-2026. It does not maintain a publicly accessible website, LinkedIn profile, or media presence beyond standard regulatory filings. This opacity is unusual for an IRB, which typically seeks visibility to reassure sponsors and regulators of its credentials. The firm's structural differentiator, if any, remains opaque due to sparse disclosure. Without a visible governance framework or published roster, its market position among IRBs — such as Western IRB, Advarra, or the WCG Group — cannot be assessed.